布南色林

更新时间：2024-01-03 13:40:17

布南色林结构式	常用名	布南色林	英文名	Blonanserin
	CAS号	132810-10-7	分子量	367.503
	密度	1.1±0.1 g/cm3	沸点	540.8±50.0 °C at 760 mmHg
	分子式	C₂₃H₃₀FN₃	熔点	117-119°C
	MSDS	中文版美版	闪点	280.9±30.1 °C
	符号	GHS07	信号词	Warning

布南色林用途

Blonanserin(AD-5423)是D2/5-HT2受体拮抗剂。

中文名	布南色林
英文名	Blonanserin
中文别名	布南瑟林 \| 2-(4-乙基-1-哌嗪基)-4-(4-氟苯基)-5,6,7,8,9,10-六氢环辛[b]吡啶 \| 布兰色林
英文别名	更多

描述	Blonanserin(AD-5423)是D2/5-HT2受体拮抗剂。
相关类别	信号通路 >> G 蛋白偶联受体/G 蛋白 >> 5-HT受体信号通路 >> 神经信号通路 >> 5-HT受体信号通路 >> G 蛋白偶联受体/G 蛋白 >> 多巴胺受体信号通路 >> 神经信号通路 >> 多巴胺受体研究领域 >> 神经疾病
参考文献	[1]. Tenjin, T., et al., Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr Dis Treat, 2013. 9: p. 587-94. [2]. Oka, M., et al., Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther, 1993. 264(1): p. 158-65.

描述

Blonanserin(AD-5423)是D2/5-HT2受体拮抗剂。

相关类别

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 5-HT受体

信号通路 >> 神经信号通路 >> 5-HT受体

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 多巴胺受体

信号通路 >> 神经信号通路 >> 多巴胺受体

研究领域 >> 神经疾病

参考文献

[1]. Tenjin, T., et al., Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr Dis Treat, 2013. 9: p. 587-94.

[2]. Oka, M., et al., Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther, 1993. 264(1): p. 158-65.

密度	1.1±0.1 g/cm3
沸点	540.8±50.0 °C at 760 mmHg
熔点	117-119°C
分子式	C₂₃H₃₀FN₃
分子量	367.503
闪点	280.9±30.1 °C
精确质量	367.242371
PSA	19.37000
LogP	6.03
外观性状	white to off-white
蒸汽压	0.0±1.4 mmHg at 25°C
折射率	1.557
储存条件	Refrigerator
水溶解性	DMSO: ≥10mg/mL

布南色林MSDS英文版

符号	GHS07
信号词	Warning
危害声明	H302-H413
危害码 (欧洲)	Xn
风险声明 (欧洲)	22
危险品运输编码	NONH for all modes of transport
RTECS号	GY0175140

Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics.

Clin. Neuropharmacol. 36(6) , 223-38, (2013)

Schizophrenia is a serious, chronic, and devastating mental illness with a substantial impact on psychological, physical, social, and economical areas of an individual and society. To treat such criti...

Blonanserin in the treatment of delirium.

Psychiatry Clin. Neurosci. 65(4) , 389-91, (2011)

The purpose of the present study was to provide preliminary data on the usefulness and safety of blonanserin for patients with delirium in the intensive care unit (ICU). The charts of 32 consecutive p...

Five Alzheimer's disease cases with refractory behavioural psychological symptoms of dementia treated with blonanserin.

Psychogeriatrics 10(4) , 198-200, (2010)

The aim of the present study was to determine the efficacy, side-effects and tolerability of blonanserin for treating refractory behavioural psychological symptoms of dementia (BPSD). The present stud...

2-(4-Ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine

2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine

Lonasen

Blonanserin

Cycloocta[b]pyridine, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro-